Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence
Meta-analysisHumansOther animals
- Design
- Meta-analysis
- Subjects
- 33 eligible human and animal studies
- Dose used in the study
- Varied
- Duration
- Not applicable
- What was measured
- Neurobehavioural and biological outcomes in animal models of neurodegeneration and in human neurocognitive disorders
What the authors reported
In animal models the compound improved memory and learning and reduced oxidative, inflammatory and astrocyte markers, with the authors noting the protective effect may matter less once disease is established. Limited human research suggested less fatigue and cognitive impairment, and the cognitive finding was confirmed in a meta-analysis of three eligible human studies, with gains in executive function, working memory, language and daily activities.
Limits of this study
Most of the 33 studies are in animals, and the human pooled result rests on three small studies; the authors call the meta-analysis preliminary. The human trials in this area on this site are small (Assogna 2020 and 2025, Caltagirone 2016). One author consults for GW Pharma outside this work. Udine group, which also runs PEA trials in psychiatry.
Source
PubMed 36387000 · doi:10.3389/fpsyt.2022.1038122
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.